Welcome to our dedicated page for Summit Therapeutics news (Ticker: SMMT), a resource for investors and traders seeking the latest updates and insights on Summit Therapeutics stock.
Summit Therapeutics Inc. (NASDAQ: SMMT) is a biopharmaceutical oncology company whose news flow is closely tied to the development of its lead investigational therapy, ivonescimab (SMT112 in Summit’s territories). Ivonescimab is described by the company as a potential first-in-class bispecific antibody targeting PD-1 and VEGF in a single molecule, and it is being evaluated in multiple Phase III clinical trials in non-small cell lung cancer (NSCLC) and colorectal cancer (CRC).
News about Summit frequently covers clinical milestones for ivonescimab, including updates from the global Phase III HARMONi trial in EGFR-mutated NSCLC after third-generation EGFR TKI therapy, as well as HARMONi-3 and HARMONi-7 in first-line metastatic NSCLC and HARMONi-GI3 in first-line unresectable metastatic CRC. Company announcements have highlighted progression-free survival and overall survival data, hazard ratios, response rates, and safety profiles, along with presentations at major conferences such as the World Conference on Lung Cancer, SITC, and ESMO.
Investors following SMMT news will also see regulatory and corporate updates, including Summit’s submission of a Biologics License Application to the U.S. FDA for ivonescimab plus chemotherapy in EGFR-mutated NSCLC, Fast Track designation for the HARMONi setting, and summaries of Akeso’s HARMONi-A trial in China, which demonstrated a statistically significant overall survival benefit for ivonescimab plus chemotherapy versus chemotherapy alone.
Additional news items cover financing activities such as private placements and at-the-market offerings, inducement stock option grants under Nasdaq Listing Rule 5635(c)(4), and collaboration announcements. Notably, Summit has reported a clinical trial collaboration with GSK plc to evaluate ivonescimab in combination with GSK’s investigational B7-H3-targeting antibody-drug conjugate, risvutatug rezetecan (GSK’227), across multiple solid tumor settings including small cell lung cancer.
For readers tracking SMMT, the news stream provides insight into Summit’s late-stage oncology pipeline, regulatory interactions, capital-raising efforts, and partnerships that shape the company’s development path.
Summit Therapeutics (NASDAQ: SMMT) has granted inducement awards of stock options to ten new employees. The collective total of options allows for the purchase of up to 249,550 shares of common stock. These awards were granted on October 1, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4) and approved by the Company's Compensation Committee.
The options have a ten-year term and an exercise price of $20.10 per share, matching the closing price of Summit's common stock on October 1, 2024. The options will vest in equal annual installments over four years and are subject to the terms of a stock option agreement to be executed by the recipients.
Summit Therapeutics (NASDAQ: SMMT) has completed enrollment for its HARMONi Phase III clinical trial, evaluating ivonescimab plus platinum-doublet chemotherapy in EGFR-mutated NSCLC patients who progressed after 3rd generation EGFR TKI treatment. The study enrolled patients from North America, Europe, and China. Additionally, the FDA has granted Fast Track designation for ivonescimab in this indication, potentially expediting its development and review process.
The HARMONi trial's topline data is expected in mid-2025. The study's analysis will include patients from the HARMONi-A trial, which led to marketing authorization in China for ivonescimab on May 24, 2024. HARMONi is designed with dual primary endpoints of progression-free survival and overall survival.
Nuvectis Pharma's NXP900 is emerging as a promising candidate in the fight against Non-Small Cell Lung Cancer (NSCLC), particularly for patients resistant to EGFR and ALK targeted therapies. Like Summit Therapeutics' Ivonescimab, which recently outperformed Merck's Keytruda in a Phase 3 trial, NXP900 targets treatment resistance but through a different mechanism.
NXP900 inhibits SRC/YES1 kinases, key drivers of cancer survival. Preclinical studies show its potential to reverse resistance to existing therapies and enhance their effectiveness when used in combination. While still in early clinical development, NXP900's targeted approach and potential applications beyond NSCLC make it a noteworthy contender in the evolving landscape of cancer treatment.
Summit Therapeutics (NASDAQ: SMMT) presented promising data for ivonescimab, a novel bispecific antibody, at ESMO 2024. Phase II studies showed encouraging results in colorectal cancer (CRC), triple-negative breast cancer (TNBC), and head and neck squamous cell carcinoma (HNSCC).
In CRC, ivonescimab plus chemotherapy achieved an 81.8% overall response rate and 100% disease control rate. For TNBC, the combination showed a 72.4% overall response rate and 9.3-month median progression-free survival. In HNSCC, ivonescimab alone or with ligufalimab demonstrated response rates of 30% and 60%, respectively.
These results support Summit's plans to expand ivonescimab's clinical development beyond non-small cell lung cancer. The drug's safety profile was generally manageable across all studies.
Summit Therapeutics (NASDAQ: SMMT) has successfully raised $235 million through a private placement of approximately 10.35 million shares at $22.70 per share. The fundraise was led by insiders and prominent biopharma institutional investors, with $79 million coming from company insiders and $156 million from external investors. Notably, all of Summit's Section 16 officers participated in the capital raise.
The company plans to use the proceeds to advance the clinical development of ivonescimab, focusing on non-small cell lung cancer and potentially expanding into colorectal cancer and triple-negative breast cancer. The capital raise was completed without bankers' fees, maximizing the net proceeds for Summit's research and development efforts.
Summit Therapeutics (NASDAQ: SMMT) announced positive results from the Phase III HARMONi-2 trial of ivonescimab, a novel bispecific antibody, in first-line treatment of PD-L1 positive advanced NSCLC. The trial showed:
- 49% reduction in risk of disease progression or death compared to pembrolizumab
- Median PFS of 11.14 months vs 5.82 months for pembrolizumab
- Benefits across subgroups, including PD-L1 high and low expression
- Comparable safety profile to pembrolizumab
Summit plans to initiate HARMONi-7, a Phase III trial in first-line PD-L1 high advanced NSCLC, in early 2025. Additional Phase II data in other solid tumors will be presented at ESMO 2024.
Summit Therapeutics (NASDAQ: SMMT) has granted inducement awards to five new employees, consisting of options to purchase up to 102,000 shares of common stock. These awards, approved by the Company's Compensation Committee, were made in accordance with Nasdaq Listing Rule 5635(c)(4). The options, granted on September 4, 2024, have a ten-year term and an exercise price of $12.00 per share, matching the closing price of Summit's common stock on that date. The options will vest in equal annual installments over four years and are subject to the terms of a stock option agreement.
Summit Therapeutics (NASDAQ: SMMT) announced that the primary analysis of the Phase III HARMONi-2 trial for ivonescimab, their novel bispecific antibody, will be presented at WCLC 2024. The trial compared ivonescimab monotherapy to pembrolizumab monotherapy in patients with advanced NSCLC and positive PD-L1 expression. Ivonescimab achieved a statistically significant improvement in progression-free survival (PFS) across various clinical subgroups. This marks the first drug to show clinically meaningful benefit over pembrolizumab in a randomized Phase III NSCLC trial. Additionally, Phase II data on ivonescimab in the perioperative setting for resectable NSCLC will be presented.
Akeso, Inc. (HKEX: 9926.HK) announced two upcoming oral presentations of ivonescimab (PD-1/VEGF bispecific antibody) at the IASLC 2024 World Conference on Lung Cancer (WCLC24). A key presentation will feature results from the HARMONi-2/AK112-303 study, comparing ivonescimab monotherapy to pembrolizumab in patients with PD-L1 positive non-small cell lung cancer (NSCLC).
Ivonescimab has shown significant milestones, including:
- Marketing approval for EGFR-mutated NSCLC treatment in May 2024
- Statistically significant improvement in progression-free survival compared to pembrolizumab
- Acceptance of supplemental New Drug Application by China NMPA for first-line treatment of PD-L1 positive NSCLC
These developments position ivonescimab as a promising treatment option in the field of lung cancer therapy.
Summit Therapeutics (NASDAQ: SMMT) has announced the grant of inducement awards to 14 new employees. The awards consist of options to purchase a total of 453,250 shares of common stock. These options, approved by the Company's Compensation Committee, were granted on August 7, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4).
The options have a ten-year term and an exercise price of $9.40 per share, which was the closing price of Summit's common stock on the grant date. The options will vest in equal annual installments over four years and are subject to the terms of a stock option agreement to be executed by each recipient.